Image: The RP-VITA remote presence robot (Photo courtesy of InTouch Health).
A new telemedicine robot designed for remote doctor-to-patient consultation combines state-of-the-art telecommunications and autonomous navigation technology.
The RP-VITA is intended for active patient monitoring in preoperative, perioperative, and postsurgical settings, including cardiovascular, neurological, prenatal, psychological, and critical care assessments and examinations. The robot features Auto Drive (an optional advanced autonomous navigation and driving feature) and an iPad user interface that provides versatility and ease of use and for delivering high acuity telemedicine. The RP-VITA robot merges seamlessly with existing hospital processes to provide state-of-the-art audiovisual capabilities with a high-quality interactive experience.
The RP-VITA platform was designed with a full range of clinical capabilities for delivering services such as TeleStroke and TeleICU today that can be expanded to integrate patient data, and enable other important clinical functions in the future. The RP-VITA telemedicine robot is a product of InTouch Health (Santa Barbara, CA, USA), and has been approved by the US Food and Drug Administration (FDA).
“RP-VITA brings to market a true next-generation remote presence solution that will enable many new clinical applications and uses,” said Yulun Wang, PhD, Chairman and CEO of InTouch Health. “We are proud to have achieved this regulatory objective with the autonomous navigation capability for RP-VITA and are absolutely committed to the highest standards for safety and efficacy.”
“RP-VITA raises the bar for acute care telemedicine solutions for patient care delivery. The Robot allows me to effortlessly follow the entire clinical workflow process, and puts me at the point of care precisely when and where I need to be,” said Paul Vespa, MD, director of neurocritical care at the UCLA Health System (Los Angeles, CA, USA). “As a thought-leader in today’s challenging health care environment, we at UCLA are very pleased to have participated in the clinical development and validation of this revolutionary heath care delivery platform.”
UCLA Health System